BRAF and cancer: In particular, Sorafenib is able to inhibit B-Raf [21] and VEGFR-2 [20,22,23,24,25,26], which are overexpressed in many cancers including HCC, RCC, thyroid carcinoma, non-small lung, breast, colorectal and ovarian cancers.